Evaluation of Crestor® (Rosuvastatin) in Daily Practice

AstraZeneca602 enrolled

Overview

This open label, non-interventional study is to show the efficacy of Crestor (rosuvastatin) in reduction of LDL-cholesterol and cardiovascular risk parameters in patients with hypercholesterolemia. Effectiveness is to be evaluated using the difference in LDL cholesterol level between the first and the second visit after 12 weeks.

Study Type

OBSERVATIONAL

Enrollment

602

Conditions

Hypercholesterolemia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * a patient with hypercholesterolemia who has been prescribed Crestoraccording to physician's judgement, irrespective of the inclusion in the study. * no treatment with any statin in the last 3 months Exclusion Criteria: * hypersensitivity to rosuvastatin or any other ingredient of Crestor * active liver disease, severe renal insufficiency * myopathy or predisposing risk factors for myopathy/ rhabdomyolysis * woman of child-bearing potential and not using appropriate contraceptive measures, pregnancy or lactation

Outcomes

Primary Outcomes

LDL-cholesterol reduction

Time frame: 12 weeks

Secondary Outcomes

achievement of target levels of total cholesterol and LDL-cholesterol

Time frame: 12 weeks

patient compliance

Time frame: 12 weeks

change in coronary risk

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.